Cataldi Fabio 4
4 · Landos Biopharma, Inc. · Filed Sep 7, 2022
Insider Transaction Report
Form 4
Cataldi Fabio
Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
2022-09-05+400,000→ 400,000 totalExercise: $0.89Exp: 2032-09-04→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]25% of the shares of common stock underlying this option will vest and become exercisable on September 5, 2023 and the remaining shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.